Searchable abstracts of presentations at key conferences in oncology

oa0001p043 | (1) | PacRim7

Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer

Portman Neil , Milioli Heloisa , Yong Aliza , Coulson Rhiannon , Alexandrou Sarah , Lam Natasha , Haupt Sue , Haupt Ygal , Caldon C Elizabeth , Lim Elgene

Estrogen Receptor (ER) signalling, upregulation of the cyclin/CDK pathway, and suppression of p53 form a critical axis controlling proliferation of ER positive breast cancer. In this setting, mutation of p53 is relatively rare and suppression of p53 function can be achieved via regulators MDM2 and MDMX. Activation of p53 by inhibition of MDM2 is a promising therapeutic target in p53 wildtype tumours and several drugs are currently in clinical trials. We hypothesised that the M...